Article Text
Abstract
Background Patients’ reported outcomes and their perspectives around their therapeutic management is a field of continuously increasing relevance in gynecological oncology. We report the results of the Berlin dialog on seven patient-reported parameters and outcomes concerning chemotherapy and maintenance treatment in patients with gynecological cancer.
Methods Key opinion leaders in gynecological oncology from different European counties and representatives of leading patients’ advocate groups in Berlin held a consensus meeting in Berlin on April 6, 2019. Seven topics of interest were identified in advance around quality of life, iatrogenic toxicity, treatment decision-making processes, sexuality, participation in clinical trials, second opinion, and long-term survivors with the the following standard operating procedure for processing and discussion: (1) agreement on its relevance; (2) literature review, and (3) discussion and consensus statements.
Results All main topics reached a consensus approval. The defined statements emphasized the importance of patients’ role in incorporating and establishing quality of life as an outcome parameter in clinical trials. Furthermore, discussants raised the importance of identifying new tools for reflecting patient-reported iatrogenic toxicity as well as emphasizing patients’ rights in providing personal information, access to second opinion in the decision-making process, and their participation in clinical trials.
Conclusion The results of this round table meeting could help redefine perspectives on the discussed topics and the importance for therapeutic management as well as for trial designs.
- Quality of Life (PRO)/Palliative Care
- medical oncology
- ovarian cancer
Statistics from Altmetric.com
Footnotes
Twitter @asociacionASACO
Contributors RA: conceptualization, moderation and organisation of the round table, summarizing, writing, editing of manuscript. SA: presenter at the round table, expert for QoL in trials. AP: literature research, data acquisition, manuscript writing. FC: manuscript writing. NC: expert in gynecological oncology, conceptualization, manuscript editing. AGM: expert in gynecological oncology, conceptualization, manuscript editing. MG: expert in gynecological oncology, conceptualization, manuscript editing. MRM: expert in gynecological oncology, conceptualization, manuscript editing. JS: expert in gynecological oncology, conceptualization, manuscript editing, corresponding author. CH: presenter at round table, patient advocacy group representative, conceptualization, manuscript editing. BL: presenter at round table, patient advocacy group representative, conceptualization, manuscript editing. EU: presenter at round table, patient advocacy group representative, conceptualization, manuscript editing. CF: conceptualization, manuscript editing. AK: presenter at round table, patient advocacy group representative, conceptualization, manuscript editing. JV: presenter at round table, patient advocacy group representative, conceptualization, manuscript editing. MR: conceptualization, manuscript editing. JH: nursing specialist, manuscript editing, conceptualization of the round table.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data sharing not applicable as no datasets generated and/or analysed for this study. Data are available upon reasonable request. No data are available. Data will be available upon request.